Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

A Practical Guide to Autoantibody Testing in Rheumatic Diseases

Donald Thomas, MD, FACP, FACR, RhMSUS, & Jason Liebowitz, MD  |  Issue: October 2024  |  

Up to 30% of treated SLE patients become ANA negative over time.17,18 When we see a new patient with a previous diagnosis of SLE who is ANA negative during the evaluation, it is imperative you obtain previous records and review the initial results on which the diagnosis of SLE was based. Assuming the patient does not have SLE because the ANA is negative and stopping therapy without exercising due diligence and executing a previous record review could be catastrophic.

Donald Thomas, MD, FACP, FACR, RhMSUS, is a rheumatologist who specializes in caring for patients with lupus and Sjögren’s disease at Arthritis and Pain Associates of P.G. County, Greenbelt, Md. He is the author of The Lupus Encyclopedia: A Comprehensive Guide for Patients and Health Care Providers. He also enjoys teaching at the Walter Reed National Military Medical Center as a clinical associate professor of medicine at the Uniformed Services University, Bethesda, Md.

ADVERTISEMENT
SCROLL TO CONTINUE

Jason Liebowitz, MD, is an assistant professor of medicine in the Division of Rheumatology at Columbia University Vagelos College of Physicians and Surgeons, New York.

Disclosures

Dr. Thomas has spoken for Exagen Diagnostics Inc. and is a scientific advisor for Progentec Diagnostics.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Schur PH. Know your labs. The Rheumatologist. 2009 Feb. https://www.the-rheumatologist.org/article/know-your-labs.
  2. Schur PH. Know your labs, Part 2. The Rheumatologist. 2009 Apr. https://www.therheumatologist.org/article/know-your-labs-part-2.
  3. Schur PH. Laboratory testing for diagnosis, management of patients with rheumatic disease. The Rheumatologist. 2014 Dec.
  4. Thomas DE, Liebowitz J. What’s holding back biomarker innovation, & how can we solve it? The Rheumatologist. 2023 Oct.
  5. Irure-Ventura J, López-Hoyos M. The past, present, and future in antinuclear antibodies (ANA). Diagnostics (Basel). 2022 Mar 7;12(3):647.
  6. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 Oct 16;349(16):1526–1533.
  7. Shome M, Chung Y, Chavan R, et al. Serum autoantibodyome reveals that healthy individuals share common autoantibodies. Cell Rep. 2022 May 31;39(9):110873.
  8. Solomon DH, Kavanaugh AJ, Schur PH, et al. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum. 2002 Aug;47(4):434–444.
  9. Vulsteke JB, Van Hoovels L, Willems P, et al. Titre-specific positive predictive value of antinuclear antibody patterns. Ann Rheum Dis. 2021 Aug;80(8):e128.
  10. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400–1412.
  11. Qin S, Wang X, Wang J, et al. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis. Lupus. 2024 Feb;33(2):111–120.
  12. Bossuyt X. DFS70 Autoantibodies: Clinical utility in antinuclear antibody testing. Clin Chem. 2024 Feb 7;70(2):374–381.
  13. Eriksson C, Kokkonen H, Johansson M, et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011 Feb 22;13(1):R30.
  14. Choi MY, Clarke AE, St Pierre Y, et al. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. Arthritis Care Res (Hoboken). 2019 Jul;71(7):893–902.
  15. Pérez D, Gilburd B, Azoulay D, et al. Antinuclear antibodies: Is the indirect immunofluorescence still the gold standard or should be replaced by solid phase assays? Autoimmun Rev. 2018 Jun;17(6):548–552.
  16. Blomberg S, Ronnblom L, Wallgren AC, et al. Anti-SSA/Ro antibody determination by enzyme-linked immunosorbent assay as a supplement to standard immunofluorescence in antinuclear antibody screening. Scand J Immunol. 2000 Jun;51(6):612–617.
  17. Wallace DJ, Silverman SL, Conklin J, et al. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. Lupus Sci Med. 2016 Feb 1;3(1):e000127.
  18. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168–1178.

Related Articles